Barclays PLC Increases Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Barclays PLC lifted its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 273.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 80,295 shares of the company’s stock after purchasing an additional 58,776 shares during the quarter. Barclays PLC owned about 0.11% of Ventyx Biosciences worth $175,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Palumbo Wealth Management LLC acquired a new stake in Ventyx Biosciences in the 3rd quarter valued at about $26,000. China Universal Asset Management Co. Ltd. grew its holdings in Ventyx Biosciences by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after acquiring an additional 5,310 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Ventyx Biosciences in the 3rd quarter valued at approximately $42,000. The Manufacturers Life Insurance Company raised its holdings in shares of Ventyx Biosciences by 41.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after purchasing an additional 7,096 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Ventyx Biosciences during the 2nd quarter worth $58,000. 97.88% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Ventyx Biosciences

In other news, CEO Raju Mohan bought 238,248 shares of the stock in a transaction dated Friday, November 22nd. The shares were acquired at an average price of $1.83 per share, with a total value of $435,993.84. Following the completion of the acquisition, the chief executive officer now directly owns 1,913,276 shares in the company, valued at approximately $3,501,295.08. The trade was a 14.22 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John Nuss sold 13,161 shares of the stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $2.26, for a total transaction of $29,743.86. Following the transaction, the insider now directly owns 485,701 shares of the company’s stock, valued at $1,097,684.26. This represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have purchased 630,000 shares of company stock worth $1,262,415. 18.18% of the stock is currently owned by insiders.

Ventyx Biosciences Stock Up 4.1 %

Shares of VTYX stock opened at $2.52 on Wednesday. The stock’s 50-day moving average price is $2.29 and its 200 day moving average price is $2.29. The stock has a market capitalization of $178.19 million, a PE ratio of -1.07 and a beta of 0.55. Ventyx Biosciences, Inc. has a 52-week low of $1.67 and a 52-week high of $11.48.

Wall Street Analyst Weigh In

A number of research firms have weighed in on VTYX. HC Wainwright restated a “neutral” rating and issued a $6.00 price target on shares of Ventyx Biosciences in a research note on Monday, November 11th. Oppenheimer reiterated an “outperform” rating and issued a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Ventyx Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.